Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01157871 · ClinicalTrials.gov registry record · Phase 2
Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01157871 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 36 participants.
The verdict
NCT01157871, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary objective is to assess safety and efficacy of two different doses of NV1FGF as compared to placebo. The secondary objective is to assess the pharmacokinetics of NV1FGF and FGF-1 protein.
Interventions
- DRUG placebo
- DRUG XRP0038 (NV1FGF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01157871
The ClinicalTrials.gov registry entry for NCT01157871 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01157871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01157871 about?
NCT01157871 is a clinical study titled "Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication". The primary objective is to assess safety and efficacy of two different doses of NV1FGF as compared to placebo. The secondary objective is to assess the pharmacokinetics of NV1FGF and FGF-1 protein.
What is the current status of trial NCT01157871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2004-06. Estimated completion is 2005-08.
What interventions are being tested in trial NCT01157871?
The interventions under investigation include: placebo (DRUG), XRP0038 (NV1FGF) (DRUG).
Who is sponsoring clinical trial NCT01157871?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.